.jpg)
Professor of Medicine
University of Colorado Anschutz Medical Campus School of Medicine
Aurora, Colorado, United States
Dr. Low Wang (pronounced “lowwong”), is an endocrinologist and Professor of Medicine at University of Colorado, Clinician-Scientist at CPC Clinical Research, and a fellow of the American College of Physicians. She earned her medical degree at the University of Rochester and did her residency and chief residency in Internal Medicine at the University of Utah. She completed her fellowship in Endocrinology, Metabolism, and Diabetes at the University of Colorado (CU) and joined the CU faculty, initially at the VA where she did research on a VA career development award to understand cellular mechanisms of atherosclerosis, then moving to the University of Colorado School of Medicine in 2012. Dr. Low Wang currently chairs the FDA Endocrinologic and Metabolic Drugs Advisory Committee. She helps design and run clinical trials for drugs, devices, and biologics, oversees medical safety for clinical trials, and adjudicates major adverse cardiovascular and limb events, and bleeding end points for international multi-center trials. She is the principal investigator for continuous glucose monitoring trials in the inpatient setting, remote continuous monitoring to facilitate a dietary intervention in rural Colorado, and lead investigator for a phase 1 trial of mesenchymal stem cell therapy for diabetic foot ulcer. Dr. Low Wang also directs the Glucose Management Team at the University of Colorado Hospital. She teaches medical students, house staff, fellows, and peers in a number of settings, and is a member of the Academy of Medical Educators. She is the founding Program Director for the primary care Diabetes Fellowship Program at CU. She has served on a number of committees for the Endocrine Society and is currently on the Nominating Committee. She is past chair of the American Association of Clinical Endocrinology Disease State Network in Diabetes and is on the Task Force for the Update of the AACE Consensus Statement Comprehensive Type 2 Diabetes Management Algorithm. She serves on the Lifestyle Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health for the American Heart Association.
Thursday, May 4, 2023
11:30 AM – 12:15 PM
Saturday, May 6, 2023
9:00 AM – 12:30 PM